NO20080433L - Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene - Google Patents

Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Info

Publication number
NO20080433L
NO20080433L NO20080433A NO20080433A NO20080433L NO 20080433 L NO20080433 L NO 20080433L NO 20080433 A NO20080433 A NO 20080433A NO 20080433 A NO20080433 A NO 20080433A NO 20080433 L NO20080433 L NO 20080433L
Authority
NO
Norway
Prior art keywords
respiratory tract
administration
inflammatory conditions
active protein
conditions affecting
Prior art date
Application number
NO20080433A
Other languages
English (en)
Norwegian (no)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of NO20080433L publication Critical patent/NO20080433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20080433A 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene NO20080433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002773 WO2007012976A2 (fr) 2005-06-24 2006-06-23 Administration aux voies aeriennes de proteine c activee dans des condition inflammatoire affectant la voie respiratoire

Publications (1)

Publication Number Publication Date
NO20080433L true NO20080433L (no) 2008-03-19

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Country Status (15)

Country Link
US (3) US8088728B2 (fr)
EP (3) EP1896059B1 (fr)
JP (3) JP2008543925A (fr)
KR (2) KR20080071116A (fr)
CN (2) CN101262880A (fr)
AU (2) AU2006260599A1 (fr)
BR (2) BRPI0613137A2 (fr)
CA (2) CA2612597C (fr)
DK (3) DK1898945T3 (fr)
HK (1) HK1114567A1 (fr)
IL (2) IL188221A0 (fr)
NO (2) NO20080433L (fr)
RU (2) RU2496516C2 (fr)
WO (3) WO2006136963A2 (fr)
ZA (2) ZA200800255B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063005A1 (en) * 2006-12-11 2010-03-11 Kaare Fiala Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin
KR102068010B1 (ko) 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 염증성 피부 질환의 치료
CN106573040B (zh) 2014-04-16 2021-07-06 Zz生物技术有限责任公司 治疗异常皮肤瘢痕形成
EP3512539A4 (fr) * 2016-09-13 2020-07-29 Prothera Biologics, Inc. Procédés de traitement d'une maladie pulmonaire à l'aide de protéines inhibitrices d'inter-alpha

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
WO1998032459A1 (fr) * 1997-01-29 1998-07-30 University Technology Corporation Activateur du plasminogene utilise comme agent anti-inflammatoire
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002087605A2 (fr) * 2001-05-02 2002-11-07 Novo Nordisk A/S Facteur vii modifie pour le traitement du syndrome de detresse respiratoire aigue
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CN1604790A (zh) 2001-10-15 2005-04-06 希龙公司 通过施用组织因子途径抑制剂(tfpi)治疗严重性肺炎
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
PT1599222E (pt) * 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (fr) * 2003-11-04 2005-05-12 Novo Nordisk A/S Composition pharmaceutique contenant un polypeptide de proteine c et un regulateur de glucose sanguin
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
JP2008515908A (ja) 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療

Also Published As

Publication number Publication date
IL188221A0 (en) 2008-03-20
US20100279925A1 (en) 2010-11-04
JP2008543925A (ja) 2008-12-04
DK1898945T3 (da) 2013-03-25
US20100160218A1 (en) 2010-06-24
AU2006273696B2 (en) 2012-08-30
WO2006136962A3 (fr) 2007-07-12
CA2612597C (fr) 2015-03-31
CA2612646A1 (fr) 2006-12-28
EP1898945B1 (fr) 2012-12-19
CN101262880A (zh) 2008-09-10
EP1906994A2 (fr) 2008-04-09
BRPI0613137A2 (pt) 2010-12-21
EP1906994B1 (fr) 2014-04-23
RU2496515C2 (ru) 2013-10-27
WO2006136963A3 (fr) 2007-07-12
AU2006273696A1 (en) 2007-02-01
EP1896059A2 (fr) 2008-03-12
DK1896059T3 (da) 2013-04-08
EP1898945A2 (fr) 2008-03-19
ZA200800255B (en) 2009-04-29
JP2013151510A (ja) 2013-08-08
EP1896059B1 (fr) 2012-12-19
ZA200800251B (en) 2009-04-29
CA2612646C (fr) 2015-11-24
WO2006136962A2 (fr) 2006-12-28
JP2008543926A (ja) 2008-12-04
KR20080071116A (ko) 2008-08-01
AU2006260599A1 (en) 2006-12-28
CN101262879B (zh) 2013-04-10
KR20080074085A (ko) 2008-08-12
US8088728B2 (en) 2012-01-03
WO2007012976A2 (fr) 2007-02-01
RU2008102656A (ru) 2009-07-27
WO2006136963A2 (fr) 2006-12-28
BRPI0611710A2 (pt) 2011-12-20
RU2496516C2 (ru) 2013-10-27
WO2007012976A3 (fr) 2007-07-12
US20100297099A1 (en) 2010-11-25
HK1114567A1 (en) 2008-11-07
CN101262879A (zh) 2008-09-10
RU2008102655A (ru) 2009-07-27
DK1906994T3 (da) 2014-07-21
CA2612597A1 (fr) 2007-02-01
IL188220A0 (en) 2008-03-20
NO20080434L (no) 2008-03-17

Similar Documents

Publication Publication Date Title
Chignalia et al. The glycocalyx and trauma: a review
Butterfield The Power of Anacrusis
NO20080433L (no) Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
WO2015016761A8 (fr) Cellules souches mésenchymateuses dans le traitement de maladies inflammatoires pulmonaires
Wösten-van Asperen et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin
NO20083658L (no) Cyanoisokinolinforbindelser som stabiliserer hypoksi induserbar faktor(HIF)
ATE516285T1 (de) Dihydropyridinonderivate
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
Brunini et al. Inhibition of l‐arginine transport in platelets by asymmetric dimethylarginine and NG‐monomethyl‐l‐arginine: Effects of arterial hypertension
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
Pilecki et al. Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis
NO20071824L (no) Fremgangsmater til a behandle trakeale, bronkiale eller alveolaere blodninger eller hemoptyse
EP2322646A8 (fr) Procédé pour détecter la thrombose de plaquettes sanguines ou des lésions à un organe
Wang et al. Airway epithelial dysfunction in the development of acute lung injury and acute respiratory distress syndrome
Lau et al. Enhanced fibrinolysis protects against lung ischemia–reperfusion injury
NO20054556L (no) Amylinaggregeringsinhibitorer og anvendelse derav
Zuliani-Alvarez et al. A virological view of tenascin-C in infection
JP2009520696A5 (fr)
NO20062360L (no) Et universelt anvendelig virus-inaktivert blodplasma fremstilt fra deler av ikke-kaukasisk plasma
ATE431755T1 (de) Filternder abscheider für partikelbelastete gase
Bain et al. Measures of Classical and Alternative Complement Function in Serum as Markers in Critical Care
Muhammed et al. Assessment of pulmonary artery pressure in chronic obstructive pulmonary disease patients without resting hypoxemia
Chen Dabigatran etexilate overdose
Eapen et al. M1 And M2 Macrophage Populations In The Airways Of Smokers And COPD Patients: Insights From Both Airway Tissue And Lumen
Tian et al. Collagen Accumulation Does Not Impair Cardiopulmonary Recovery From Hypoxia, As Assessed Via Admittance Derived Pressure-Volume Loops In Mice